在类风湿性关节炎 (TARA) 中使用阿托瓦斯塔丁的试验:双盲,随机化,安慰剂对照试验
David W McCarey1, Iain B McInnes, Rajan Madhok
1Centre for Rheumatic Diseases, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.
Lancet (London, England)
|June 23, 2004
概括
在六个月的时间里,阿托瓦斯塔丁显著降低了类风湿性关节炎患者的疾病活性和炎症标志物. 这项研究表明,他类药物.
科学领域:
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
背景情况:
- 类风湿性关节炎 (RA) 涉及膜炎,关节破坏和加速动脉样硬化.
- 类他类药物 (HMG-CoA减少酶抑制剂) 降低血管风险,可能具有免疫调节作用.
- 这项研究研究了他类药物在降低RA炎症和血管风险方面的潜力.
研究的目的:
- 评估阿托瓦斯塔丁在减少类风湿性关节炎炎炎症标志物和疾病活性方面的疗效.
- 评估阿托瓦斯塔丁对 RA 患者血管风险因素的影响.
主要方法:
- 一个为期6个月的双盲,安慰剂对照试验,涉及116名RA患者.
- 患者接受了40毫克阿托瓦斯塔丁或安慰剂,作为现有的疾病修饰性抗风湿药物 (DMARD) 治疗的辅助.
- 主要结局包括疾病活动评分 (DAS28) 和欧洲反风湿联盟 (EULAR) 响应标准的变化.
主要成果:
- 与安慰剂相比,阿托瓦斯塔丁显著改善了DAS28得分 (p=0.004).
- 在接受阿托瓦斯塔丁治疗的患者中,更高的比例实现了EULAR反应 (31%对10%,p=0.006).
- 使用阿托瓦斯塔丁观察到C-反应蛋白,红细胞沉积率和胀关节数量的显著减少.
结论:
- 阿托瓦斯塔丁在RA患者中表现出适度但临床显著的抗炎作用.
- 这些发现表明,他类药物可以在自身免疫性炎症的背景下修改血管风险因素.
- 在阿托瓦斯塔丁和安慰剂组之间,不良事件是相似的.
相关概念视频
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...